Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Fate Therapeutics (FATE)

$24.18 0.62 (2.50%)

16:14 EDT FATE Stock Quote Delayed 20 Minutes

Volume:

Previous Close $24.80

Market Cap 1.28B

PE Ratio -23.03

EPS -1.05

Volume (Avg. Vol.) 1.79M

Day's Range 23.62 - 25.35

52-Week Range 12.59 - 32.39

Dividend & Yield N/A (N/A)

FATE Stock Predictions, Articles, and Fate Therapeutics News

From InvestorPlace
From the Web

3 Top Drug Stocks to Own In 2020

By Ian Cooper Jan 3, 2020

Some of the biggest catalysts for future growth in drug stocks include the millions of retiring baby boomers, and new innovative treatments for a variety of medical issues.

My Top Biotech Stocks to Buy in the Market Crash

From The Motley Fool Apr 7, 2020

The worst is yet to come for the stock market, but these biopharma companies have promising potential.

Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session

From Zacks Investment Research Apr 6, 2020

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

74 Biggest Movers From Friday

From Benzinga Apr 6, 2020

Gainers BioSig Technologies, Inc. (NASDAQ: BSGM) shares gained 42.4% to close at $5.14 on Friday. BioSig is expected to host telebriefing on development updates regarding...

Fate Therapeutics (FATE) Received its Third Buy in a Row

From Smarter Analyst Apr 6, 2020

After SunTrust Robinson and Mizuho Securities gave Fate Therapeutics (NASDAQ: FATE) a Buy rating last month, the company received another Buy, this time

Need To Know: Analysts Are Much More Bullish On Fate Therapeutics, Inc. (NASDAQ:FATE) Revenues

From Simply Wall St Apr 4, 2020

Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year’s forecasts. The analysts have sharply increased their revenue numbers,<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/need-to-know-analysts-are-much-more-bullish-on-fate-therapeutics-inc-nasdaqfate-revenues/">Read More...</a></div>

7 Promising Biotech Stocks in a Postpandemic World

From Barron's Apr 3, 2020

Casdin Capital’s Eli Casdin highlights seven promising life-sciences stocks, including bluebird bio, Invitae, and Crispr Therapeutics

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy